Clinical trial · Observational
Retrospective Data Collection: Post Study Treatment Anticancer Therapy From IMELDA MO22223
Retrospective Data Collection: Post Study Treatment Anticancer Therapy From All Randomized Patients Involved in IMELDA MO22223
NCT02383576CI-TRIAL-00032499completedResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to understand better the effective results from the IMELDA MO22223 P-trial (NCT00929240) and see if the anti-cancer therapies given during its follow-up time after study treatments were terminated possibly had an effect on efficacy results.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No Intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Bevacizumab
- description
- Participants who received bevacizumab in IMELDA (MO22223) P-trial and were in maintenance phase were observed.
- interventionNames
- Other: No Intervention
- label
- Bevacizumab and Capecitabine
- description
- Participants who received bevacizumab and capecitabine in IMELDA (MO22223) P-trial and were in maintenance phase were observed.
- interventionNames
- Other: No Intervention
Primary outcomes (5)
- measure
- Percentage of Participants Who Prematurely Withdrawn From Maintenance Therapy
- timeFrame
- Up to 78 months
- description
- Participants who had prematurely withdrawn from maintenance study treatment were reported. The retrospectively collected data was pooled with the data collected within the IMELDA (MO22223) P-trial to allow a statistically meaningful analysis.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Having been randomized in the IMELDA MO22223 P-trial Exclusion Criteria: Not having been randomized in the IMELDA MO22223 P-trial
References
Publications (0)
Data not yet available
No reference posted for this study.